Nothing Special   »   [go: up one dir, main page]

BRPI0409450B8 - composições farmacêuticas, úteis para o tratamento ou controle de infecções bacterianas por administração parenteral, processos para a sua produção e respectivos usos - Google Patents

composições farmacêuticas, úteis para o tratamento ou controle de infecções bacterianas por administração parenteral, processos para a sua produção e respectivos usos

Info

Publication number
BRPI0409450B8
BRPI0409450B8 BRPI0409450A BRPI0409450A BRPI0409450B8 BR PI0409450 B8 BRPI0409450 B8 BR PI0409450B8 BR PI0409450 A BRPI0409450 A BR PI0409450A BR PI0409450 A BRPI0409450 A BR PI0409450A BR PI0409450 B8 BRPI0409450 B8 BR PI0409450B8
Authority
BR
Brazil
Prior art keywords
processes
treatment
production
pharmaceutical compositions
control
Prior art date
Application number
BRPI0409450A
Other languages
English (en)
Inventor
Luther Ofslager Christian
Marc Cohen Jonathan
Bakir Fawzi Mahdi
Muzafar Shah Syed
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0409450(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0409450A publication Critical patent/BRPI0409450A/pt
Publication of BRPI0409450B1 publication Critical patent/BRPI0409450B1/pt
Publication of BRPI0409450B8 publication Critical patent/BRPI0409450B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"composições que contêm peperacilina e tazobactamo, úteis para injeção". constatou-se que um agente quelador de ácido aminocarboxílico, preferivelmente, edta, ou um sal do mesmo é útil para inibir a formação de partículas em combinações parenterais de piperacilina/tazobactamo. a composição também pode conter um tamponador, preferivelmente, citrato, e, opcionalmente, um aminoglicosídio. o produto pode estar na forma de uma composição congelada, que pode ser descongelada para uso. o produto também pode estar na forma de um pó criodessecado, que pode ser reconstituído por adição de um veículo aquoso, para tornar a formar uma solução.
BRPI0409450A 2003-04-14 2004-04-07 composições farmacêuticas, úteis para o tratamento ou controle de infecções bacterianas por administração parenteral, processos para a sua produção e respectivos usos BRPI0409450B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46280803P 2003-04-14 2003-04-14
PCT/US2004/010698 WO2004091666A1 (en) 2003-04-14 2004-04-07 Compositions containing piperacillin and tazobactam useful for injection

Publications (3)

Publication Number Publication Date
BRPI0409450A BRPI0409450A (pt) 2006-05-02
BRPI0409450B1 BRPI0409450B1 (pt) 2016-07-12
BRPI0409450B8 true BRPI0409450B8 (pt) 2021-05-25

Family

ID=32326726

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409450A BRPI0409450B8 (pt) 2003-04-14 2004-04-07 composições farmacêuticas, úteis para o tratamento ou controle de infecções bacterianas por administração parenteral, processos para a sua produção e respectivos usos

Country Status (35)

Country Link
US (3) US7498312B2 (pt)
EP (1) EP1468697B1 (pt)
JP (1) JP4644659B2 (pt)
KR (1) KR100824554B1 (pt)
CN (1) CN1802179B (pt)
AR (1) AR043863A1 (pt)
AT (1) ATE381947T1 (pt)
AU (1) AU2004229407B2 (pt)
BR (1) BRPI0409450B8 (pt)
CA (1) CA2464258C (pt)
CH (1) CH695185A9 (pt)
CL (1) CL2004000782A1 (pt)
CO (1) CO5700796A2 (pt)
CR (2) CR8035A (pt)
CY (1) CY1108064T1 (pt)
DE (1) DE602004010862T2 (pt)
DK (1) DK1468697T3 (pt)
EC (1) ECSP056100A (pt)
ES (1) ES2298672T3 (pt)
FR (1) FR2853547B1 (pt)
GB (1) GB2400557B (pt)
HK (1) HK1069775A1 (pt)
IL (1) IL171337A (pt)
MX (1) MXPA05010996A (pt)
MY (1) MY139099A (pt)
NO (1) NO20054789L (pt)
NZ (1) NZ543005A (pt)
PL (1) PL1468697T3 (pt)
PT (1) PT1468697E (pt)
RU (2) RU2322980C2 (pt)
SA (1) SA04250119B1 (pt)
SI (1) SI1468697T1 (pt)
TW (1) TWI308069B (pt)
WO (1) WO2004091666A1 (pt)
ZA (1) ZA200508315B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110209B2 (en) * 2002-12-20 2012-02-07 Xeris Pharmaceuticals Inc. Intracutaneous injection
DE602004010862T2 (de) * 2003-04-14 2009-01-02 Wyeth Holdings Corp. Zusammensetzungen enthaltend Piperacillin und Tazobactam zur Injektion
EP1799209A1 (en) * 2004-10-14 2007-06-27 Wyeth Compositions containing piperacillin, tazobactam and a aminocarboxilic acid in a sodium lactate diluent
US8273732B2 (en) * 2004-12-02 2012-09-25 Venus Remedies Limited Compositions for combating beta-lactamase-medicated antibiotic resistance using beta-lactamase inhibitors useful for injection
ES2284318B1 (es) * 2005-04-13 2008-11-01 Labiana Development, S.L. Procedimiento de obtencion de una mezcla en polvo de una sal sodica de piperaciclina y tazobactama, util para su administracion por via inyectable.
ITMI20051630A1 (it) 2005-09-02 2007-03-03 Acs Dobfar Spa Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN1927201B (zh) * 2006-08-25 2011-06-01 天津和美生物技术有限公司 含哌拉西林的抗生素复方
CN102441169A (zh) * 2006-08-25 2012-05-09 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN101129383B (zh) * 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
CN102210679B (zh) * 2006-08-25 2013-03-13 天津和美生物技术有限公司 含哌拉西林的抗生素复方
CN101265263B (zh) * 2008-05-12 2010-06-02 海南百那医药发展有限公司 哌拉西林钠他唑巴坦钠复方注射剂的生产方法
WO2010013640A1 (ja) * 2008-07-28 2010-02-04 Yamaguchi Keizo 感染症治療効果増強剤
JP5852316B2 (ja) * 2010-03-30 2016-02-03 富山化学工業株式会社 ピペラシリン含有懸濁液の製造法
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
BR112013012735B1 (pt) 2010-11-25 2021-11-23 Allecra Therapeutics Gmbh Composição farmacêutica inibidora de ss-lactamase
AU2012225268B2 (en) 2011-03-10 2016-10-20 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
AU2012332556B2 (en) 2011-10-31 2016-05-26 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
KR101935484B1 (ko) 2012-03-26 2019-01-04 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 함유 점안액
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
KR101816798B1 (ko) * 2012-10-19 2018-01-10 주식회사유한양행 피페라실린 또는 그의 염, 타조박탐 또는 그의 염 및 덱사메타손 포스페이트 또는 그의 염을 포함하는 국소투여용 약학 조성물
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US20140274994A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Stabilizing ceftolozane
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274997A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Cephalosporin pharmaceutical compositions
EP3043797B1 (en) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
JP6382997B2 (ja) 2014-02-07 2018-08-29 エクセセーラ ファーマシューティカルズ インコーポレイテッド 治療用化合物および組成物
CN106573106B (zh) 2014-08-06 2021-06-22 Xeris药物公司 用于皮内和/或皮下注射糊剂的注射器、试剂盒和方法
CN106714799A (zh) * 2014-10-08 2017-05-24 泽井制药株式会社 冷冻干燥制剂的制造方法
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
BR112017022864A2 (pt) * 2016-03-31 2018-07-17 Wockhardt Ltd composições antibacterianas
WO2018025248A1 (en) * 2016-08-05 2018-02-08 Jodas Expoim Private Limited Edta injection and process for making the same
ES2982668T3 (es) 2017-06-02 2024-10-17 Xeris Pharmaceuticals Inc Formulaciones de fármacos de moléculas pequeñas resistentes a la precipitación
US11110054B2 (en) * 2018-05-09 2021-09-07 Slayback Pharma Llc Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
CN112618486B (zh) * 2020-12-24 2023-07-18 浙江昂利康制药股份有限公司 一种注射用混悬油剂及其制备方法
CN113209030B (zh) * 2021-04-27 2023-04-25 海南通用康力制药有限公司 哌拉西林钠他唑巴坦钠无菌粉针剂的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477452A (en) * 1981-03-26 1984-10-16 American Cyanamid Company Composition of matter comprising a lyophilized preparation of a penicillin derivative
US4534977A (en) * 1981-03-26 1985-08-13 American Cyanamid Company Composition of matter comprising a low bulk density lyophilized preparation of Sodium Piperacillin
US4562073A (en) * 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
US5763480A (en) * 1994-02-14 1998-06-09 The Jewish Hospital Of St. Louis Inhibitors of cell-medicated disorders
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6207661B1 (en) 1999-02-22 2001-03-27 Baxter International Inc. Premixed formulation of piperacillin sodium and tazobactam sodium injection
WO2003088914A2 (en) * 2002-04-18 2003-10-30 The University Of Iowa Research Foundation Methods of inhibiting and treating bacterial biofilms by metal chelators
DE602004010862T2 (de) * 2003-04-14 2009-01-02 Wyeth Holdings Corp. Zusammensetzungen enthaltend Piperacillin und Tazobactam zur Injektion
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
AU2003230899A1 (en) * 2003-04-14 2004-11-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection

Also Published As

Publication number Publication date
GB2400557A (en) 2004-10-20
RU2007142454A (ru) 2009-05-27
CY1108064T1 (el) 2014-02-12
CN1802179B (zh) 2011-09-14
US20060234995A1 (en) 2006-10-19
AR043863A1 (es) 2005-08-17
PT1468697E (pt) 2008-03-05
PL1468697T3 (pl) 2008-05-30
GB2400557B (en) 2005-06-15
RU2005135135A (ru) 2006-06-10
ECSP056100A (es) 2006-03-01
US20110166091A1 (en) 2011-07-07
BRPI0409450B1 (pt) 2016-07-12
CN1802179A (zh) 2006-07-12
NO20054789D0 (no) 2005-10-18
EP1468697B1 (en) 2007-12-26
ES2298672T3 (es) 2008-05-16
CA2464258C (en) 2005-06-07
FR2853547B1 (fr) 2006-08-04
KR20060014375A (ko) 2006-02-15
CO5700796A2 (es) 2006-11-30
US20090176720A1 (en) 2009-07-09
SI1468697T1 (sl) 2008-04-30
CR8035A (es) 2006-05-30
US7498312B2 (en) 2009-03-03
IL171337A (en) 2011-03-31
SA04250119B1 (ar) 2008-03-30
RU2322980C2 (ru) 2008-04-27
CH695185A5 (fr) 2006-01-13
DK1468697T3 (da) 2008-04-14
US7915229B2 (en) 2011-03-29
ZA200508315B (en) 2008-04-30
TW200503758A (en) 2005-02-01
AU2004229407B2 (en) 2010-04-22
CR9792A (es) 2008-09-23
AU2004229407A1 (en) 2004-10-28
MXPA05010996A (es) 2005-12-12
NZ543005A (en) 2009-03-31
GB0407853D0 (en) 2004-05-12
JP4644659B2 (ja) 2011-03-02
TWI308069B (en) 2009-04-01
BRPI0409450A (pt) 2006-05-02
CH695185A9 (fr) 2006-02-28
CL2004000782A1 (es) 2005-03-04
HK1069775A1 (en) 2005-06-03
CA2464258A1 (en) 2004-10-14
JP2006523695A (ja) 2006-10-19
DE602004010862T2 (de) 2009-01-02
MY139099A (en) 2009-08-28
WO2004091666A8 (en) 2005-11-10
WO2004091666A1 (en) 2004-10-28
US8133883B2 (en) 2012-03-13
NO20054789L (no) 2005-12-13
DE602004010862D1 (de) 2008-02-07
KR100824554B1 (ko) 2008-04-24
ATE381947T1 (de) 2008-01-15
FR2853547A1 (fr) 2004-10-15
EP1468697A1 (en) 2004-10-20

Similar Documents

Publication Publication Date Title
BRPI0409450B8 (pt) composições farmacêuticas, úteis para o tratamento ou controle de infecções bacterianas por administração parenteral, processos para a sua produção e respectivos usos
CL2015002412A1 (es) Composición farmacéutica sólida de daptomicina; método de fabricación; y uso para tratar infecciones bacterianas (divisional de la sol. 1336-2012)
BR0108828A (pt) Formulação de carboidrato (adjuvante pré-biótico) para aperfeiçoamento de resposta imuno
BRPI0710485B1 (pt) composições líquidas úteis no tratamento de doenças respiratórias
Prywer et al. Bacterially induced formation of infectious urinary stones: recent developments and future challenges
ES2136883T3 (es) Nueva formulacion mejorada de aminoglucosido para administracion en forma de aerosol.
NZ595526A (en) Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
BR9915208A (pt) Preparado farmacêutico de moxifloxacina
CN108578268B (zh) 一种含有溶菌酶的牙膏
JP2019536761A5 (pt)
BRPI0707488B8 (pt) método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável
CR9857A (es) Composiciones de suplemento de hierro con tolerancia mejorada
MXPA02011389A (es) Forma de administracion farmaceutica para peptidos, procedimiento para su preparacion y aplicacion.
BRPI0408918A (pt) formulação parenteral de ácido micofenólico, um sal ou pró-droga do mesmo
SI1561460T1 (sl) Nanodelci za aplikacijo uäśinkovin, postopek za pripravo teh delcev in sestavek, ki jih vsebuje
DE602006016785D1 (de) Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung
BR0209206A (pt) Clatrato de hidrato de azitromicina com 1,2-propileno glicol, processo para a sua preparação e composição farmacêutica compreendendo o mesmo
BRPI0606119A2 (pt) preparações injetáveis de diclofenaco e seus sais farmaceuticamente aceitáveis
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
HUP9801712A2 (hu) Racemizálás ellen stabilizált, cilansetrontartalmú gyógyászati készítmények, előállításuk és a stabilizáló adalékanyagok alkalmazása
BRPI0412295A (pt) composições herbáceas para o tratamento e a prevenção de distúrbios da próstata
US20110256237A1 (en) Methods and compositions for treating acne vulgaris and acne rosacea
BRPI0515598A (pt) preparado de ferro iónico e ferro hemìnico e suas variantes para profilaxia e tratamento de deficiencia de ferro
MX2007007911A (es) Composicion farmaceutica granular estable de solifenacina o su sal.
TH72832A (th) สารผสมซึ่งมีพิเพอราซิลลินและตาโซแบคแตมที่มีประโยชน์สำหรับการฉีด

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PARA: INT. CL. A61K 47/18, 31/43

Ipc: A61K 47/18 (2011.01), A61K 31/43 (2011.01), A61P 3

Free format text: PARA: INT. CL. A61K 47/18, 31/43; A61P 31/04

Ipc: A61K 47/18 (2011.01), A61K 31/43 (2011.01), A61P 3

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/07/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved